• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Vaxart Inc (NQ: VXRT )

    0.7008 -0.0192 (-2.67%)
    Streaming Delayed Price Updated: 10:23 AM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Vaxart Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside
    Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a bullish outlook on its oral vaccines for COVID-19 and norovirus. 
    Via Benzinga
    Exposures COVID-19
    VXRT Stock Earnings: Vaxart Misses EPS, Beats Revenue for Q2 2024
    VXRT stock results show that Vaxart missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
    Via InvestorPlace
    $1M Bet On This Penny Stock? Check Out These 4 Stocks Under $2 Insiders Are Aggressively Buying
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Recap: Vaxart Q4 Earnings
    Via Benzinga
    Vaxart's Earnings: A Preview
    Via Benzinga
    What's Going On With Vaxart Stock Today?
    Vaxart shares are trading higher by around 8% Wednesday afternoon. The company recently secured a contract from the U.S. Government via the Department of Health and Human Services. 
    Via Benzinga
    Vaxart's Earnings Outlook
    Via Benzinga
    Vaxart Stock Is Moving Higher After The Bell: What's Going On?
    Vaxart, a clinical-stage biotechnology company developing a range of oral recombinant vaccines, announced Monday that proceeds from a recent offering combined with reimbursements under its Project... 
    Via Benzinga
    Vaxart Bags $453M Worth BARDA-Funded Project, Seeks To Raise $40M Via Equity Offering
    Vaxart (VXRT) shares surged 23% in premarket session after receiving a $453 million project award from BARDA to conduct a COVID-19 vaccine study. 
    Via Benzinga
    Exposures COVID-19
    Why Adobe Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning! 
    Via InvestorPlace
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    Palo Alto Networks Shares Drop After Q3 Results, In-Line Guidance: The Details
    Palo Alto Networks reported quarterly earnings of $1.32 per share which beat the analyst consensus estimate of $1.25 by 5.6%. Quarterly sales clocked in at $1.985 billion which beat the analyst... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    VXRT Stock Earnings: Vaxart Meets EPS, Beats Revenue for Q1 2024
    VXRT stock results show that Vaxart met analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Vaxart Stock Climbs After Blockbuster Q1 Revenue
    Vaxart reported quarterly losses of 14 cents per share, inline with the analyst consensus estimate. Quarterly sales clocked in at $2.181 million, beating the analyst consensus estimate of $800,000 by... 
    Via Benzinga
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
    These seven companies were the top 2020 stocks. After their glory years have faded, they are looking to turn their fortunes around. 
    Via InvestorPlace
    VXRT Stock Earnings: Vaxart Beats EPS, Beats Revenue for Q4 2023
    VXRT stock results show that Vaxart beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Wednesday's Intraday Session
    Via Benzinga
    Earnings Scheduled For March 14, 2024
    Companies Reporting Before The Bell • Pharming (NASDAQ:PHAR) is projected to report earnings for its fourth quarter. 
    Via Benzinga
    Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Advanced Micro Devices, Inc. (NASDAQ: AMD) shares declined 3.8% to $165.49 following fourth-quarter results. AMD reported fourth-quarter non-GAAP earnings per share of 77 cents per share on... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    What's Going On With Vaxart (VXRT) Stock?
    Vaxart shares are trading higher by 17.8% Tuesday morning amid multiple news items. The company recently secured a contract from the U.S. Government via the Department of Health and Human Services. 
    Via Benzinga
    Earnings Scheduled For November 2, 2023
    Companies Reporting Before The Bell • AudioCodes (NASDAQ:AUDC) is estimated to report quarterly earnings at $0.18 per share on revenue of $61.52 million. 
    Via Benzinga
    Why Biophytis Shares Are Trading Higher By Over 12%: Here Are 20 Stocks Moving Premarket
    Gainers 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    It's time to dive into the biggest pre-market stock movers as we start the trading week on Monday with the hottest coverage! 
    Via InvestorPlace
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.